select a format

Single User License
USD 1500 INR 96390
Site License
USD 3000 INR 192780
Corporate User License
USD 4500 INR 289170

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Vectura Group Plc-Product Pipeline Review-2015

Vectura Group Plc-Product Pipeline Review-2015


  • Products Id :- GMDHC07277CDB
  • |
  • Pages: 37
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Vectura Group Plc-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Vectura Group plc-Product Pipeline Review-2015', provides an overview of the Vectura Group plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vectura Group plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Vectura Group plc including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Vectura Group plc's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Vectura Group plc's pipeline products

Reasons To Buy

Evaluate Vectura Group plc's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Vectura Group plc in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Vectura Group plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Vectura Group plc and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vectura Group plc

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Vectura Group plc and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Vectura Group Plc Snapshot 5

Vectura Group Plc Overview 5

Key Information 5

Key Facts 5

Vectura Group Plc-Research and Development Overview 6

Key Therapeutic Areas 6

Vectura Group Plc-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

Vectura Group Plc-Pipeline Products Glance 14

Vectura Group Plc-Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

Vectura Group Plc-Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Vectura Group Plc-Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Vectura Group Plc-Drug Profiles 18

VR-475 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

VR-876 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

VR-096 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

VR-647 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

VR-736 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drug for Pulmonary Hypertension 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

VR-588 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Vectura Group Plc-Pipeline Analysis 25

Vectura Group Plc-Pipeline Products by Target 25

Vectura Group Plc-Pipeline Products by Route of Administration 26

Vectura Group Plc-Pipeline Products by Molecule Type 27

Vectura Group Plc-Pipeline Products by Mechanism of Action 28

Vectura Group Plc-Recent Pipeline Updates 29

Vectura Group Plc-Dormant Projects 31

Vectura Group Plc-Discontinued Pipeline Products 32

Discontinued Pipeline Product Profiles 32

VR-611 32

Vectura Group Plc-Company Statement 33

Vectura Group Plc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

Vectura Group Plc, Key Information 5

Vectura Group Plc, Key Facts 5

Vectura Group Plc-Pipeline by Indication, 2015 7

Vectura Group Plc-Pipeline by Stage of Development, 2015 8

Vectura Group Plc-Monotherapy Products in Pipeline, 2015 9

Vectura Group Plc-Partnered Products in Pipeline, 2015 10

Vectura Group Plc-Partnered Products/ Combination Treatment Modalities, 2015 11

Vectura Group Plc-Out-Licensed Products in Pipeline, 2015 12

Vectura Group Plc-Out-Licensed Products/ Combination Treatment Modalities, 2015 13

Vectura Group Plc-Phase III, 2015 14

Vectura Group Plc-Phase II, 2015 15

Vectura Group Plc-Phase I, 2015 16

Vectura Group Plc-Preclinical, 2015 17

Vectura Group Plc-Pipeline by Target, 2015 25

Vectura Group Plc-Pipeline by Route of Administration, 2015 26

Vectura Group Plc-Pipeline by Molecule Type, 2015 27

Vectura Group Plc-Pipeline Products by Mechanism of Action, 2015 28

Vectura Group Plc-Recent Pipeline Updates, 2015 29

Vectura Group Plc-Dormant Developmental Projects,2015 31

Vectura Group Plc-Discontinued Pipeline Products, 2015 32

Vectura Group Plc, Subsidiaries 35

List of Figures

Vectura Group Plc-Pipeline by Top 10 Indication, 2015 7

Vectura Group Plc-Pipeline by Stage of Development, 2015 8

Vectura Group Plc-Monotherapy Products in Pipeline, 2015 9

Vectura Group Plc-Partnered Products in Pipeline, 2015 10

Vectura Group Plc-Out-Licensed Products in Pipeline, 2015 12

Vectura Group Plc-Pipeline by Top 10 Target, 2015 25

Vectura Group Plc-Pipeline by Top 10 Route of Administration, 2015 26

Vectura Group Plc-Pipeline by Top 10 Molecule Type, 2015 27

Vectura Group Plc-Pipeline Products by Top 10 Mechanism of Action, 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Vectura Group plc; Vectura Group plc - Key Therapeutics; Vectura Group plc - Pipeline Overview and Promising Molecules; Vectura Group plc - News; Vectura Group plc - Latest Updates; Vectura Group plc - Pipeline; Vectura Group plc - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com